The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Novartis inks agreement to buy Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD: Basel Friday, May 2, 2025, 14:00 Hrs [IST] Novartis annou ...

Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to ...

Novartis has agreed to buy Regulus Therapeutics for up to $1.7 billion, giving the Swiss drugmaker access to an experimental ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic ...

Novartis AG (NVS) reports robust sales and income growth, while navigating challenges and enhancing its product pipeline.

Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company that launched nearly two decades ago with plans to make drugs capable of targeting small ...

With future approvals of FABHALTA, the market size is expected to expand significantly in the coming years, driven by its potential to address unmet medical needs across multiple conditions like ...

A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: With future approvals of FABHALTA, the market size is expected to expand ...